These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 24920577)

  • 1. Cigarette company trade secrets are not secret: an analysis of reverse engineering reports in internal tobacco industry documents released as a result of litigation.
    Velicer C; Lempert LK; Glantz S
    Tob Control; 2015 Sep; 24(5):469-80. PubMed ID: 24920577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tobacco companies' efforts to undermine ingredient disclosure: the Massachusetts benchmark study.
    Velicer C; Aguinaga-Bialous S; Glantz S
    Tob Control; 2016 Sep; 25(5):575-83. PubMed ID: 26292701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Packaging colour research by tobacco companies: the pack as a product characteristic.
    Lempert LK; Glantz S
    Tob Control; 2017 May; 26(3):307-315. PubMed ID: 27255118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tobacco company efforts to influence the Food and Drug Administration-commissioned Institute of Medicine report clearing the smoke: an analysis of documents released through litigation.
    Tan CE; Kyriss T; Glantz SA
    PLoS Med; 2013; 10(5):e1001450. PubMed ID: 23723740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tobacco industry argues domestic trademark laws and international treaties preclude cigarette health warning labels, despite consistent legal advice that the argument is invalid.
    Crosbie E; Glantz SA
    Tob Control; 2014 May; 23(3):e7. PubMed ID: 23179728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tobacco-control policies in tobacco-growing states: where tobacco was king.
    Fallin A; Glantz SA
    Milbank Q; 2015 Jun; 93(2):319-58. PubMed ID: 26044632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transparency as a remedy against racketeering: preventing and restraining fraud by exposing Big Tobacco's dirty secrets.
    Muggli ME; Crystal HM; Klausner K
    Tob Control; 2015 Sep; 24(5):514-8. PubMed ID: 25052863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "If we can just 'stall' new unfriendly legislations, the scoreboard is already in our favour": transnational tobacco companies and ingredients disclosure in Thailand.
    MacKenzie R; Collin J; Sriwongcharoen K; Muggli ME
    Tob Control; 2004 Dec; 13 Suppl 2(Suppl 2):ii79-87. PubMed ID: 15564225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The toxic effects of cigarette additives. Philip Morris' project mix reconsidered: an analysis of documents released through litigation.
    Wertz MS; Kyriss T; Paranjape S; Glantz SA
    PLoS Med; 2011 Dec; 8(12):e1001145. PubMed ID: 22205885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tobacco industry lawyers as "disease vectors".
    Guardino SD; Daynard RA
    Tob Control; 2007 Aug; 16(4):224-8. PubMed ID: 17652236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cigarettes with defective filters marketed for 40 years: what Philip Morris never told smokers.
    Pauly JL; Mepani AB; Lesses JD; Cummings KM; Streck RJ
    Tob Control; 2002 Mar; 11 Suppl 1(Suppl 1):I51-61. PubMed ID: 11893815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failed promises of the cigarette industry and its effect on consumer misperceptions about the health risks of smoking.
    Cummings KM; Morley CP; Hyland A
    Tob Control; 2002 Mar; 11 Suppl 1(Suppl 1):I110-7. PubMed ID: 11893821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prying open the door to the tobacco industry's secrets about nicotine: the Minnesota Tobacco Trial.
    Hurt RD; Robertson CR
    JAMA; 1998 Oct; 280(13):1173-81. PubMed ID: 9777818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tobacco company strategies to identify and promote the benefits of nicotine.
    Ling PM; Glantz SA
    Tob Control; 2019 May; 28(3):289-296. PubMed ID: 30093414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tobacco industry strategies to attract young smokers in Spain: a review of companies' internal documents].
    Soto Mas F; Jacobson HE; Fernández E
    Adicciones; 2011; 23(4):327-34. PubMed ID: 22249897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of tobacco ingredients on smoke chemistry. Part I: Flavourings and additives.
    Baker RR; Pereira da Silva JR; Smith G
    Food Chem Toxicol; 2004; 42 Suppl():S3-37. PubMed ID: 15072836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secret science: tobacco industry research on smoking behaviour and cigarette toxicity.
    Hammond D; Collishaw NE; Callard C
    Lancet; 2006 Mar; 367(9512):781-7. PubMed ID: 16517278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roadmap to a tobacco epidemic: transnational tobacco companies invade Indonesia.
    Hurt RD; Ebbert JO; Achadi A; Croghan IT
    Tob Control; 2012 May; 21(3):306-12. PubMed ID: 21852413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tobacco industry targeting of health-conscious youth with 'lighter' cigarettes: the case of Singapore.
    van der Eijk Y; Tan GPP
    Tob Control; 2021 Nov; 30(e1):e20-e26. PubMed ID: 33067408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementation of graphic health warning labels on tobacco products in India: the interplay between the cigarette and the bidi industries.
    Sankaran S; Hiilamo H; Glantz SA
    Tob Control; 2015 Nov; 24(6):547-55. PubMed ID: 24950697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.